Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery
Launched by A.T. RESOLVE SARL · Dec 30, 2014
Trial Information
Current as of April 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation in the capsular bag.
- Exclusion Criteria:
- • Any additional surgical procedures at the time of the cataract surgery
- • Refractive surgery in the study eye within the past 2 years
- • History or presence of noninfectious inflammatory ocular disease (e.g., episcleritis, scleritis, uveitis) in either eye
- • Intraocular pressure of \> 21 mm Hg in either eye
- • Proliferative or severe nonproliferative diabetic retinopathy in either eye
- • Neovascular/wet age-related macular degeneration in either eye
About A.T. Resolve Sarl
a.t. resolve sarl is a clinical trial sponsor focused on advancing innovative therapeutic solutions through rigorous research and development. Committed to enhancing patient outcomes, the organization specializes in conducting high-quality clinical studies across various therapeutic areas. With a team of experienced professionals and a robust infrastructure, a.t. resolve sarl collaborates with healthcare providers, regulatory bodies, and industry partners to ensure the successful execution of clinical trials, adherence to regulatory standards, and the integration of patient-centric approaches in the development of new therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Murray Hill, New Jersey, United States
Patients applied
Trial Officials
Tomasz Sablinski, MD
Study Director
Auven Therapeutics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials